Mutation update for the SATB2 gene by Zarate, Yuri A. et al.
Received: 4 February 2019 | Revised: 10 April 2019 | Accepted: 22 April 2019
DOI: 10.1002/humu.23771
MUTAT I ON UPDAT E
Mutation update for the SATB2 gene
Yuri A. Zarate1 | Katherine A. Bosanko1 | Aisling R. Caffrey2 | Jonathan A. Bernstein3 |
Donna M. Martin4 | Marc S. Williams5 | Elizabeth M. Berry‐Kravis6 | Paul R. Mark7 |
Melanie A. Manning8 | Vikas Bhambhani9 | Marcelo Vargas9 | Andrea H. Seeley5 |
Juvianee I. Estrada‐Veras10,11,12 | Marieke F. vanDooren13 | Maria Schwab14 |
Adeline Vanderver15,16 | Daniela Melis17 | Adnan Alsadah18 | Laurie Sadler19 |
Hilde Van Esch20 | Bert Callewaert21 | Ann Oostra22 | Jane Maclean23 |
Maria Lisa Dentici24 | Valeria Orlando25 | Mark Lipson26 | Steven P. Sparagana27 |
Timothy J. Maarup28 | Suzanne IM Alsters29 | Ariel Brautbar30 |
Eliana Kovitch31 | Sakkubai Naidu32 | Melissa Lees33 | Douglas M. Smith34 |
Lesley Turner35 | Víctor Raggio36 | Lucía Spangenberg37 | Sixto Garcia‐Miñaúr38 |
Elizabeth R. Roeder39,40 | Rebecca O. Littlejohn39,40 | Dorothy Grange41 |
Jean Pfotenhauer42 | Marilyn C. Jones43 | Meena Balasubramanian44 |
Antonio Martinez‐Monseny45 | Lot Snijders Blok46,47 | Ralitza Gavrilova48 |
Jennifer L. Fish49
1Section of Genetics and Metabolism, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas
2Health Outcomes, College of Pharmacy, Department of Pharmacy Practice, University of Rhode Island, Kingston, Rhode Island
3Department of Pediatrics, Stanford University School of Medicine, Stanford, California
4Departments of Pediatrics and Human Genetics, The University of Michigan, Ann Arbor, Michigan
5Genomic Medicine Institute, Geisinger, Danville, Pennsylvania
6Departments of Pediatrics, Neurological Sciences, Biochemistry, Rush University Medical Center, Chicago, Illinois
7Division of Medical Genetics, Spectrum Health, Grand Rapids, Michigan
8Departments of Pathology and Pediatrics, Stanford University School of Medicine, Stanford, California
9Division of Genetics and Genomic Medicine, Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota
10Murtha Cancer Center Research Program, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland
11Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
12Pediatric subspecialty‐Medical Genetics Service, Walter Reed National Military Medical Center, Bethesda, Maryland
13Department of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
14Genetics Division, Joseph Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, New Jersey
15Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
16Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
17Department of Translational Medical Science, Section of Pediatrics, Federico II University, Naples, Italy
18Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio
19Division of Genetics, Oishei Children's Hospital, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, New York
20Department of Human Genetics, University Hospitals Leuven, KU, Leuven, Belgium
21Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
22Department of Pediatric Neurology, Ghent University Hospital, Ghent, Belgium
23Pediatric Neurology, Palo Alto Medical Foundation, San Jose, California
Human Mutation. 2019;40:1013–1029. wileyonlinelibrary.com/journal/humu © 2019 Wiley Periodicals, Inc. | 1013
24Medical Genetics, Academic Department of Pediatrics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy
25Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
26Department of Genetics, Kaiser Permanente, Sacramento, California
27Department of Neurology, Texas Scottish Rite Hospital for Children, Dallas, Texas
28Department of Genetics, Kaiser Permanente, Los Angeles, California
29Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
30Department of Genetics, Cook Chldren's Medical Center, Fort Worth, Texas
31PANDA Neurology, Atlanta, Georgia
32Department of Neurogenetics, Kennedy Krieger Institute, Baltimore, Maryland
33Department of Clinical Genetics, Great Ormond Street Hospital for Children, London, UK
34Minnesota Epilepsy Group, Saint Paul, Minnesota
35Discipline of Genetics, Faculty of Medicine, Memorial University, St. John's, Newfoundland, Canada
36Departamento de Genética, Facultad de Medicina, Montevideo, Uruguay
37Unidad de Bioinformática, Institut Pasteur, Montevideo, Uruguay
38Department of Medical Genetics, Hospital Universitario La Paz, Madrid, Spain
39Department of Pediatrics, Baylor College of Medicine, San Antonio, Texas
40Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
41Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medcine, St Louis, Missouri
42Division of Medical Genetics and Genomic Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
43Division of Genetics, Department of Pediatrics, University of California, San Diego and Rady Children's Hospital, San Diego, California
44Sheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Western Bank, Sheffield, UK
45Genetics and Molecular Medicine Department, Rare Disease Pediatric Unit, Hospital Sant Joan de Déu, Barcelona, Spain
46Human Genetics Department, Radboud University Medical Center, Nijmegen, The Netherlands
47Language & Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands
48Departments of Neurology and Clinical Genomics, Mayo Clinic, Rochester, Minnesota
49Department of Biological Sciences, University of Massachusetts Lowell, Lowell, Massachusetts
Correspondence
Yuri A. Zarate, M.D., Arkansas Children's
Hospital, 1 Children's Way; Slot 512‐22, Little
Rock, AR 72202.
Email: yazarate@uams.edu
Abstract
SATB2‐associated syndrome (SAS) is an autosomal dominant neurodevelopmental
disorder caused by alterations in the SATB2 gene. Here we present a review of
published pathogenic variants in the SATB2 gene to date and report 38 novel
alterations found in 57 additional previously unreported individuals. Overall, we
present a compilation of 120 unique variants identified in 155 unrelated families
ranging from single nucleotide coding variants to genomic rearrangements
distributed throughout the entire coding region of SATB2. Single nucleotide variants
predicted to result in the occurrence of a premature stop codon were the most
commonly seen (51/120 = 42.5%) followed by missense variants (31/120 = 25.8%).
We review the rather limited functional characterization of pathogenic variants and
discuss current understanding of the consequences of the different molecular
alterations. We present an expansive phenotypic review along with novel genotype‐
phenotype correlations. Lastly, we discuss current knowledge of animal models and
present future prospects. This review should help provide better guidance for the
care of individuals diagnosed with SAS.
K E YWORD S
genotype‐phenotype correlation, pathogenic variants, SATB2, SATB2‐associated syndrome,
whole exome sequencing
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1 | BACKGROUND
SATB2‐associated syndrome (SAS; MIM# 612313, Glass syndrome) is
an autosomal dominant disorder first reported in 1989 in a 16‐year‐
old male with severe intellectual disability and an interstitial deletion
of 2q32.2‐2q33.1 (Glass, Swindlehurst, Aitken, McCrea, & Boyd,
1989). Clinically, SAS is characterized by developmental delay/
intellectual disability with absent or limited speech development,
palatal and dental abnormalities, feeding difficulties, behavioral
problems, and dysmorphic facial features (Docker et al., 2014; Zarate
et al., 2015; Zarate, Smith‐Hicks et al., 2018). Other supportive
findings such as skeletal anomalies with low bone density
and abnormal brain neuroimaging have been described
(Zarate, Smith‐Hicks et al., 2018; Zarate, Steinraths et al., 2018).
SAS is caused by the alterations of SATB2 that can include single
nucleotide variants (loss‐of‐function as well as missense), intragenic
deletions and duplications, contiguous deletions, and translocations
with secondary gene disruption (Zarate & Fish, 2017; Zarate, Kaylor,
& Fish, 1993). While haploinsufficiency of SATB2 seems the most
likely mechanism of disease, a dominant negative effect has been
suggested in at least one instance in an individual with a nonsense
variant (Leoyklang et al., 2013). The SATB2 gene maps to 2q32‐q33
and has three transcripts (NM_001172509, NM_001172517, and
NM_015265), codes for SATB2, an 82.6 kDa protein of 733 amino
acids.
SATB2 binds to nuclear matrix‐attachment regions (MARs) where
it organizes chromatin to regulate tissue‐specific gene regulatory
networks (GRNs), and thus has critical roles in multiple develop-
mental processes (Britanova et al., 2006; Dobreva, Dambacher, &
Grosschedl, 2003; Dobreva et al., 2006; Gyorgy, Szemes, de Juan
Romero, Tarabykin, & Agoston, 2008). The SATB2 protein has two
CUT domains and a homeodomain (FitzPatrick et al., 2003) that are
highly conserved across vertebrate taxa (FitzPatrick et al., 2003;
Sheehan‐Rooney, Palinkasova, Eberhart, & Dixon, 2010). The CUT
domains and homeodomains are both DNA‐binding motifs, which
may bind DNA independently or cooperatively.
Clinically, SAS has been characterized through two large cohort
studies (Bengani et al., 2017; Zarate, Smith‐Hicks et al., 2018). We
recently presented the common clinical features and natural history
of 72 individuals with SAS due to a variety of molecular mechanisms.
In this study, we review the previously described individuals with SAS
and present 57 additional individuals that expand the mutation
spectrum seen in this condition and describe novel genotype‐
phenotype correlations. All families reported for the first time were
enrolled under a research clinical registry protocol approved by the
Institutional Review Board of the University of Arkansas for Medical
Sciences.
2 | VARIANTS
All SATB2 variants are described according to current HGVS
mutation nomenclature guidelines based on Genbank accession
number NM_015265 (den Dunnen et al., 2016). Novel variants are
interpreted using ACMG classification recommendations (Richards
et al., 2015). This report excludes larger deletions and duplications
that encompass SATB2 along with adjacent genes.
Tables 1,2 detail all 101 previously published SATB2 intragenic
alterations in the international peer‐reviewed literature (PubMed
database) and the Human Gene Mutation Database (HGMD
professional 2018.3; Brewer et al., 1999; Leoyklang et al., 2007;
Baptista et al., 2008; Rosenfeld et al., 2009; Tegay et al., 2009;
Balasubramanian et al., 2011; Rauch et al., 2012; Talkowski et al.,
2012; Asadollahi et al., 2014; Gilissen et al., 2014; Lieden, Kvarnung,
Nilssson, Sahlin, & Lundberg, 2014; Rainger et al., 2014; Trakadis
et al., 2014; Farwell et al., 2015; Kaiser et al., 2015; Zarate et al.,
2015; Boone et al., 2016; Lee et al., 2016; Bengani et al., 2017;
Bowling et al., 2017; Deciphering Developmental Disorders Study,
2017; Schwartz, Wilkens, Noon, Krantz, & Wu, 2017; Vissers et al.,
2017; Zarate et al., 2017; Cherot et al., 2018; Kikuiri et al., 2018; Lv
et al., 2018; Scott et al., 2018; Zarate, Smith‐Hicks et al., 2018;
Zarate, Steinraths et al., 2018). In this study, we also report
57 additional individuals with 47 SATB2 alterations (Tables 1,2) that
have been submitted to the LOVD database: https://databases.lovd.
nl/shared/genes/SATB2.
Overall, including our data and those of the literature, a total of
120 unique variants were found in 158 individuals from 155
unrelated families. While all types of pathogenic variants were
found, single nucleotide variants that are predicted to result in the
occurrence of a premature stop codon were the most commonly seen
(51/120 = 42.5%). Missense variants were also frequently found
(25.8%), followed by intragenic deletions (18.3%), translocations
(5%), splice site alterations (5%), intragenic duplications (2.5%), and
a single in‐frame alteration (0.8%; Figure S1).
2.1 | Point pathogenic variants
Eighty‐nine distinct point variants including single base substitutions
and small deletions/insertions were found in 127 individuals from
125 families (Figure 1; Liu et al., 2015). Most molecular diagnostics
were performed by whole exome sequencing (WES; 105/
127 = 82.7%) with the remaining individuals obtaining the diagnosis
through a different next‐generation sequencing platform (epilepsy,
intellectual disability or Angelman syndrome dedicated panels,
11.8%), SATB2 Sanger sequencing (3.1%), or whole genome sequen-
cing (WGS; 2.4%). De novo status was confirmed in almost all
instances when parental testing was performed (98.1%, 105/107
families), including a pair of monozygotic twins. The remaining two
instances correspond to a pair of siblings found to have the same
variant indicating germline mosaicism and a case of low‐level blood
mosaicism in a father of a single SAS‐affected individual previously
reported. Here, we present individual (SATB2‐135) with a de novo
mosaic pathogenic variant (c.1498delG) as determined by WES
(32/143 reads) and presenting with the common phenotypic features.
The 89 pathogenic variants were distributed along the entire
coding sequence of SATB2, and while variants were present in every
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coding exon (exon 3‐12), the distribution was not uniform
(Figure S2A). Unique pathogenic variants found in single individuals
were most common (Figure 1). However, 7.9% of the pathogenic
variants (7/89) were seen in two to four different families and 4.5%
(4/89) were present in five or more families. Nearly half
(41/89 = 46.1%) of the pathogenic variants were found in exons
8 and 9. There was a clear overrepresentation of exon 9 in particular
when adjusting by size of each individual exon. This suggests a
hotspot of pathogenic variants (Supp. Figure S2B).
2.1.1 | Missense variants
Thirty‐one unique missense variants were found in 49 individuals.
Most missense variants were located within exons 8 and 9
(19/31 = 61.3%; Figure S2A) and located within the CUT1 domain
(17/31 = 54.8%) of the SATB2 protein. Missense variants were often
shared by multiple individuals with alterations in codons 389
(12 individuals) and 399 (7 individuals) being particularly common,
suggesting hotspots. Most missense variants were confirmed to be de
novo (44/45 = 97.8%). To assess the predicted pathogenicity of the
11 novel variants reported in this study, Polyphen2, SIFT, Provean,
Mutation Taster, and CADD prediction programs were used
(Table S1). Ten variants were interpreted as deleterious by all five
programs, the remaining (p.Gln514Arg) with 4/5 programs predicting
damaging effects.
Functional studies have been performed for three missense
variants: c.1165C>T, p.(Arg389Cys), c.1543G>A, p.(Gly515Ser), and
c.1696G>A p.(Gln566Lys; Bengani et al., 2017). The p.Arg389Cys
change located in the CUT1 domain led to a marked increase in the
proportion of soluble fraction of the protein whereas the p.Gly515-
Ser and p.Gln566Lys variants located within the CUT2 domain and
the region between CUT2 and the HOX domains respectively had the
opposite effect. These experiments suggested a role of the CUT1
domain in initiating interaction with chromatin and a requirement for
the CUT2 domain to facilitate dissociation of SATB2 from bound
chromatin. These alterations in the kinetics of chromatin association
resulting from missense variants have been postulated to functionally
result in alterations that resemble complete loss‐of‐protein function
(Bengani et al., 2017).
2.1.2 | In‐frame insertion
A single de novo in‐frame insertion of 12 nucleotides not predicted to
alter the reading frame has been reported in SATB2: c.929_930in-
sTTGTAAGGCAAC, p.(Q310delinsHCKAT). The individual had a
history of moderate to severe intellectual disability, autism, macro-
cephaly, frontal bossing, and deep‐set eyes (Gilissen et al., 2014).
2.1.3 | Predicted truncating variants
Fifty‐one SATB2 variants reported were predicted to be disruptive to
protein production resulting in loss‐of‐function, including 5 nonsense
and 11 frameshift novel variants from this study. The variants were
distributed throughout the reading frame but were frequently found
within exons 8 to 12 (38/51 = 74.5%). Stop‐gain pathogenic variants
located within the last two exons might be expected to escape
nonsense‐mediated decay (NMD) and result in a shorter protein. In
keeping with this hypothesis, a single variant located within the last
exon of SATB2 (c.2074G>T; p.Glu692*) was shown to result in a
shorter protein consistent with the predicted 692aa protein product
of the mutant cDNA (Bengani et al., 2017). Two additional predicted
loss‐of‐function variants have been studied in greater detail:
c.715C>T (p.R239*) and c.847C>T (p.R283*) both found in six
individuals each. The c.715C>T variant located in exon 8, was
documented at the RNA level in two previously described unrelated
individuals, indicating that the RNA was stable enough to escape
NMD (Docker et al., 2014; Leoyklang et al., 2007). Further, the
translated truncated protein retained the SATB2 dimerization
domain. Through luciferase assays using a MAR sequence binding
domain, it was documented to interfere with the repressive MAR‐
regulated transcriptional activity of the wild‐type SATB2, suggesting
a dominant negative effect for this mutation (Leoyklang et al., 2013).
Conversely, the c.847C>T variant, also located in exon 8, was studied
from tooth mesenchymal cells from an affected individual. Dimin-
ished SATB2 expression by Sanger sequencing and reduced SATB2
mRNA compared to control was demonstrated for this variant,
suggesting NMD of the mutant RNA transcript (Kikuiri et al., 2018).
2.1.4 | Splice site variants
Six variants (1 novel from this study) disrupted an essential splice site
consensus sequence: three affecting the donor (5′) site at the end of
exons 4, 5, and 8, and three affecting the acceptor (3′) site at the
start of exons 7, 9, and 12. Splice‐prediction programs (MaxEntScan
and Human Splicing Finder) predicted abnormal splicing for all
variants and potential activation of cryptic donor site or acceptor site
for c.473+1delG and c.1741‐1G>A, respectively. No RNA analysis
has been performed to confirm the impact on splicing for any of
these variants.
2.2 | Large intragenic rearrangements
Twenty‐five SATB2 exonic 1–12 inclusive) rearrangements including
22 deletions (10 from this report) and three duplications have been
described (Table 2). For the 10 individuals that underwent parental
testing, de novo status was confirmed. A pair of siblings (SATB2‐02
and SATB2‐128) with an intragenic deletion from phenotypically
unaffected parents is also reported here for the first time suggesting
germline mosaicism. Except for one individual (SATB2‐92) identified
through WGS and another as part of subtelomere multiplex ligation‐
dependent probe hybridization (MLPA) analysis (SATB2‐140), all
other copy number variations were initially identified by chromoso-
mal microarray performed as part of the clinical evaluation with sizes
ranging from 10 to 317 kb for deletions and between 32 and 54 kb
for duplications (Table 2). For all individuals, SATB2 was the only
gene affected with no involvement of adjacent genes. Multi‐exonic
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rearrangements were more common (19/25 = 76.0%) than single
exon involvement (Figure 1). Abnormalities involving at least exon 7
were present in half of these individuals (14 total from 13 unrelated
families). No deletions have been documented at the cDNA level and
only 2 refined by MLPA. A single duplication was studied at the
cDNA level (Kaiser et al., 2015). In this female individual, an initial
chromosomal microarray (Cytoscan HD; Affymetrix, Santa Clara, CA)
revealed an 84‐kb duplication within chromosomal region 2q33.1
(200,256,583–200,340,204) encompassing a part of the SATB2 gene.
Reverse transcription PCR analysis with cDNA primers flanking the
duplicated exon and subsequent Sanger sequencing of the extracted
cDNA fragments showed the tandem in‐frame duplication consistent
with coexpression of transcripts with a duplicated exon and wild‐type
transcripts.
2.3 | Large chromosomal rearrangements including
2q33.1
Thirty‐five individuals with larger chromosomal alterations that
include 2q33.1 (33 deletions, 2 duplications) have been reported
TABLE 2 Intragenic SATB2 chromosomal abnormalities previously reported and from this report.
Abnormality Position Min sequence coordinates hg19 Size (kb) Methodology Reference
Intragenic deletions Exons 9–11 chr2:200,168,993‐200,203,730 35 105 K Oligo Agilent Balasubramanian et al.
(2011)
Exons 4–12 chr2:200,128,960‐200,312,555 183.6 105 K Oligo Agilent Rosenfeld et al. (2009)
Exons 3–11 chr2:200,151,982‐200,325,064 173.1 105 K Oligo Agilent Rosenfeld et al. (2009)
Exons 1–11 chr2:200,151,782‐200,336,956 185.2 105 K Oligo Agilent Rosenfeld et al. (2009)
Exons 1–8 chr2: 200,199,481‐200,340,178 141 SNP Affymetrix Zarate, Smith‐Hicks et al.
(2018)
Exons 4–8 chr2: 200,198,963‐200,314,171 115 SNP Affymetrix This report
Exons 9–10 chr2: 200,180,939‐200,200,560 19.6 OGT 60k oligo Zarate, Smith‐Hicks et al.
(2018)
Exons 1–11 chr2:200,151,782‐200,336,956 185 105 K Oligo Agilent Zarate, Smith‐Hicks et al.
(2018)
Exons 5–12 chr2: 200,018,395‐200,246,466 228 60 K Oligo Agilent Zarate, Smith‐Hicks et al.
(2018)
Exon 9 chr2:200,190,560‐200,200,832 10 Affymetrix 750k Zarate, Smith‐Hicks et al.
(2018)
Exons 2–4 chr2:200,280,770‐200,325,182 45 OGT 8 × 60k Zarate, Smith‐Hicks et al.
(2018)
Exons 5–8 chr2:200,212,737‐200,256,585 44 Affymetrix Cytoscan HD Zarate, Smith‐Hicks et al.
(2018)
Exon 4 chr2:200,292,552‐200,302,732 10.2 Affymetrix Cytoscan HD Zarate, Smith‐Hicks et al.
(2018)
Exons 4–8 chr2:200,195,604‐200,315,398 120 CombiSNP This report
Exons 8–9 chr2:200,192,250‐200,230,824 39 Affymetrix Cytoscan HD This report
Exons 1–12 chr2:200,133,428‐200,450,474 317 Agilent 8 × 60 K This report
Exons 7–8 chr2:200,197,135‐200,242,625 45.5 Affymetrix Cytoscan HD This report
Exons 7–8 chr2:200,194,727‐200,240,771 46 180k Cytosure ISCA v2 This report
Exon 5 chr2:200,246,407‐200,296,329 50 Agilent 4 × 180 K, PCR This report
Exons 1–4 chr2:200,275,266‐200,344,231 69 Oligo array+SNP This report
Exon 7 chr2:200,222,207‐200,243,660 21.4 Research WGS (MLPA
confirmed)
This report
Exon 9 1.chr2:200,193,421‐200,193,634 0.213┼ MLPA This report
Intragenic
duplications
Exon 4 chr2:200,278,502‐200,310,272 32 Affymetrix Cytoscan HD,
MLPA
Asadollahi et al. (2014)
Exon 4 chr2:200,256,546‐200,310,885 54 Affymetrix Cytoscan HD,
PCR, MLPA
Kaiser et al. (2015)
Exons 5–7 chr2:200,233,354‐200,255,458 35 180 K Oligo Agilent, MLPA Lieden et al. (2014)
Abbreviations: MLPA, multiplex ligation‐dependent probe hybridization; PCR, polymerase chain reaction.
┼The exact location of the breakpoints of this deletion is unknown as the MLPA kit used only covered limited exons.
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F IGURE 1 Schematic representation of the spectrum of SATB2 variants previously described and from this study. (a) Splicing and coding
exonic pathogenic variants. Splicing variants are represented along the genomic structure of the SATB2 gene according to NM_015265.3
including 12 exons (boxes) and introns (black horizontal lines). Exonic pathogenic variants are illustrated according to changes at the
protein level (p.) by corresponding mutation types as follows: green squares for missense variants, red diamonds for frameshift variants,
and yellow circles for nonsense variants. Codons 239 and 283 for nonsense (6 each), and 389 (12 individuals) and 399 (7 individuals) for
missense variants are affected by the highest number of pathogenic variants. Diagrams were constructed using Illustrator for Biosequence
(IBS1.0.1). (b) SATB2 intragenic rearrangements. Full boxes correspond to deletions while lighter rectangles to duplications. In case of
recurrence of the same exon being involved, the number of occurrences is indicated next to the rearrangement
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and reviewed in the past (Zarate & Fish, 2017; Zarate, Smith‐Hicks
et al. (2018)). For deletions, some of these include dozens of adjacent
genes and are as large as 26.3Mb (Rifai et al., 2010). Although
overlapping features with SAS are present in most individuals with
larger deletions, other less common abnormalities, such as genitour-
inary anomalies, cardiac defects, and ectodermal changes (other than
dental), appear to be more common (or exclusively present) when
compared with intragenic molecular alterations (Zarate & Fish,
2017). For this group of individuals with larger rearrangements of
2q33.1, it remains difficult to establish genotype/phenotype correla-
tions given the potential phenotype contribution of other genes
besides SATB2.
2.4 | Translocations
The original report of two de novo apparently balanced
autosomal translocations t(2;7)(q33;p21) and t(2;11)(q32;p14)
allowed the recognition of SATB2 as the causative gene for this
syndrome (Brewer et al., 1999). High resolution mapping of the
t(2;7) translocation showed disruption of the coding region of the
SATB2 gene between exons 2 and 3 (FitzPatrick et al., 2003),
whereas t(2;11) disrupted the long‐range cis regulatory
elements located in the centromeric gene desert 3′ of SATB2
(Rainger et al., 2014). A few additional individuals with SATB2
disruption secondary to de novo chromosomal translocations
were subsequently described to result in SAS providing further
supporting evidence for this molecular mechanism of disease
(Baptista et al., 2008; Rainger et al., 2014; Talkowski et al., 2012;
Tegay et al., 2009).
3 | BIOLOGICAL RELEVANCE
SATB2 pathogenic alterations are distributed throughout the coding
regions of the gene but exons 8, 9, and 11 are most commonly
involved. For missense variants, most (23/31 = 74.2%) are located
within the CUT1, CUT2, or HOX DNA protein domains. While the
joint function of these DNA‐binding domains is not fully clear, it is
suggested that missense variants within the core of the CUT domain
are likely to result in loss of DNA‐binding activity; CUT1 being
required to initiate interaction with chromatin and CUT2 (and the
region between CUT2 and HOX) required to facilitate dissociation of
SATB2 from bound chromatin (Bengani et al., 2017). The vast
majority of pathogenic alterations of SATB2 are null variants
(frameshift, nonsense, canonical splice site, and single or multiexon
deletions) and while predicted to result in a loss‐of‐function and
haploinsufficiency, limited functional studies have suggested a
potential dominant negative effect for some. Of note, an increasing
number of missense pathogenic variants have been described with
functional alterations that resemble the complete loss‐of‐protein
function.
4 | CLINICAL AND DIAGNOSTIC
RELEVANCE
A summary of clinical features of all 158 individuals previously
reported and from this report, excluding those with larger
deletions and duplications that include SATB2 and surrounding
genes, is presented in Table 3. With rare exceptions, SAS diagnosis
was not clinically recognized a priori. However, although the
diagnosis of SAS still relies on molecular confirmation of a
pathogenic variant in SATB2, a distinctive phenotype can often
be identified. Speech delay is present in all individuals older than
2 years of age.
TABLE 3 Demographic and phenotypic features of 158 individuals
with SATB2‐associated syndrome.
Characteristic (N with data) All patients (n = 158)
Demographics
Male (152) 90 (59.2%)
Mean age, years (152) 9.5 ± 7.5
Molecular mechanism
Missense 49 (31.0%)
Nonsense 38 (24.1%)
Frameshift 32 (20.3%)
Splicing 7 (4.4%)
In‐frame insertion 1 (0.6%)
Intragenic deletion 22 (13.9%)
Translocations 6 (3.8%)
Intragenic duplication 3 (1.9%)
Phenotype
Neurodevelopmental abnormalities
Developmental delay (157) 157 (100%)
No words for speech (152) 66 (43.4%)
Autistic behavior (145) 29 (20.0%)
Dental anomalies (137) 135 (98.5%)
Sialorrhea (109) 96 (88.1%)
Facial dysmorphism (127) 107 (84%)
Low BMD (46) 33 (71.7%)
Feeding difficulties (130) 89 (68.5%)
Hypotonia (114) 67 (58.8%)
Sleeping difficulties (109) 55 (50.5%)
Abnormal neuroimaging (108) 50 (46.3%)
Sleeping difficulties (145) 66 (45.5%)
Cleft palate (154) 70 (45.5%)
Strabismus (143) 51 (35.7%)
Agitation/aggressive (145) 45 (31.0%)
Growth retardation (144) 44 (30.6%)
Clinical seizures (143) 29 (20.3%)
Hyperactivity (145) 29 (20.0%)
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Severe expressive language delay is common with 84.3% (102/
121) of individuals older than 4 years of age having 10 or fewer
words in their expressive vocabulary, with 42.1% (51/121) demon-
strating completely absent verbal communication (Figure S3). Other
areas of neurodevelopment can also be compromised as evidenced
by an average age at the first steps of 25.5 months. Intellectual
disability has been reported in several individuals old enough to
undergo cognitive evaluations and often in the moderate to severe
range (Zarate, Smith‐Hicks et al. (2018)). Dental abnormalities are
present in all individuals and include delayed development of the
mandibular second bicuspids or the roots of the permanent teeth,
severely rotated or malformed teeth, taurodontism, and multiple
odontomas (Kikuiri et al., 2018; Scott et al., 2018). Behavioral
difficulties, feeding issues, abnormal brain neuroimaging, low bone
density, suggestive facial features, and cleft palate complete the
characteristic phenotype of SAS (Table 3). Through previous reports
and the evaluation of dozens of patients by at least a single examiner
(Y.A.Z.), broad thumbs and/or halluces appear to be another
distinctive feature, present in a third of individuals evaluated (16/
47 = 34%), that could raise the clinical suspicion of this diagnosis
(Figure 2 a).
Because the identification of SATB2 as the gene responsible
for SAS, the number of described individuals has continued to
grow over the last few years. Most current molecular cytogenetic
platforms should be able to detect exon level intragenic deletions
involving SATB2. Likewise, SATB2 is part of several commercially
available panels targeting broad phenotypes such as develop-
mental delay, autism, or seizures. As families receive counseling,
it is important to discuss the potential recurrence risk consider-
ing a few instances of suspected germline mosaicism documen-
ted. With a previous report of coding variants in siblings and the
sibling pair with intragenic deletions reported here, we estimate
a 1 to 2% germline mosaicism risk (2/155 families = 1.3%). Of
note, paternal blood mosaicism has also been documented on one
occasion. Lastly, management and surveillance guidelines for SAS
have been proposed and typically need the participation of a
multidisciplinary team with a heavy emphasis on pediatric
dentistry and speech therapy (Zarate & Fish, 2017; Zarate
et al., 1993).
5 | GENOTYPE/PHENOTYPE
CORRELATIONS
Table S2 presents detailed clinical features present in each of the
158 individuals (114 individuals enrolled in the SAS registry and 44
additional reported in the literature). We identified differences in
clinical characteristics by a molecular mechanism. Specific changes to
the gene were compared to all other changes, using either Chi‐square
or Fisher's exact tests (when at least one cell had an expected count
of less than 5) for categorical variables and t tests for continuous
variables. While there were no differences in the average age at
walking or talking, other clinically relevant distinctions were
identified (Table S3). The proportion of individuals with no verbal
words to communicate older than 4 years of age was lowest
for nonsense variants (8/29 = 27.6%) and highest for missense
F IGURE 2 (a) Broad halluces from four different individuals. (b) Composite images of individuals with nonsense, missense, and frameshift
variants. Across all three images a flat philtrum with thin vermillion of the upper lip can be recognized
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pathogenic variants mutations (20/39 = 51.3%; p = 0.0496). Indivi-
duals with missense pathogenic variants were less likely to have cleft
palate (11/49 = 22.5% vs. 59/105 = 56.2% for other groups;
p < 0.0001) but more likely to have clinical seizures (14/46 = 30.4%
vs. 15/97 = 15.5% for other groups; p = 0.0375). Conversely, indivi-
duals with nonsense variants had significantly fewer clinical seizures
(3/35 = 8.6% vs. 26/108 = 24.1% for other groups; p = 0.0474). Lastly,
individuals with frameshift variants were more likely to have feeding
difficulties (25/26 = 96.2% vs. 64/104 = 61.5% for other groups;
p = 0.0007). If this difference in the prevalence of feeding difficulties
is the result of a true biologically different mechanism for frameshift
variants compared to nonsense variants or merely the result of a
statistical anomaly, is unclear.
To determine if facial dysmorphisms were different enough
among the most common molecular mechanisms, 102 2D photo-
graphs from 69 individuals (19 nonsense, 31 missense, and 19
frameshift variants) were analyzed using Face2Gene (FDNA Inc.,
Boston, MA) analytic tool vs.18.2.0. No statistically significant
differences were found among the three composite images (Figure
2 b). However, binary comparisons for each of the three groups
against a respective age and gender‐matched cohort of typical
individuals revealed statistically significant differences for all three
groups (nonsense, p = 0.04; missense, p = 0.018; frameshift,
p = 0.019).
6 | ANIMAL MODELS
Much of what we know about SATB2 function in human development
has come from studies in animal models. In mice, Satb2 is expressed
in tissues that are affected in patients with SAS. During development,
Satb2 is expressed in upper layer neurons, neural crest progenitors of
the jaw, osteoblasts, odontoblasts, and other dental progenitor cells
(Britanova et al., 2006; Dobreva et al., 2006; He et al., 2017). In
adults, Satb2 continues to contribute to bone and brain function
through its expression in osteoblasts and pyramidal neurons of the
cerebral cortex and hippocampus (Huang et al., 2013; Jaitner et al.,
2016; Wei et al., 2012).
In general, Satb2 functions as a transcriptional regulator that is
important for tissue‐specific functions. In mice bone progenitors,
Satb2 regulates osteogenic differentiation genes (Dobreva et al.,
2006), while in postmitotic neurons Satb2 regulates expression of
genes involved in upper layer identity, synaptic transmission, and
axon guidance (Jaitner et al., 2016; Li et al., 2017; Whitton et al.,
2018). The consequence of loss of Satb2 in bone progenitors is
reduced bone size and density due to increased cell death and
reduced differentiation potential (Britanova et al., 2006; Dobreva
et al., 2006).
In murine brain development, Satb2 is required to specify
upper layer cortical neurons that project axons across the corpus
callosum to the contralateral hemisphere (Alcamo et al., 2008;
Britanova et al., 2008). Loss of Satb2 also results in reduced
branches and spine density in basal dendrites of hippocampal
neurons (Li et al., 2017). Similar to patients with SAS, Satb2+/‐
heterozygous mice have no reported corpus callosum defects
(Alcamo et al., 2008; Zarate, Smith‐Hicks et al. (2018)). However,
Satb2+/‐ heterozygous mice suffer from impaired working and
spatial memory. This deficit is exacerbated in mice where Satb2
has been deleted postnatally in hippocampal neurons (Li et al.,
2017). These mice also have difficulties in locomotion, short‐term
novel object recognition memory, and long‐term contextual fear
memory (Jaitner et al., 2016; Li et al., 2017).
Taken together, research in animal systems has provided
molecular and cellular mechanisms underlying SAS pathogenesis.
These data help outline expectations of long‐term care and provide
medical practitioners with guidance about the potential spectrum of
defects to manage in patients with SAS. However, current treatments
are symptom‐guided and do not specifically target pathogenic
mechanisms. Future research is needed to further explore potential
therapies that directly target SAS pathology.
7 | FUTURE PROSPECTS
A key avenue of future research is the use of human‐induced
pluripotent stem cells (hiPSCs) to model disease and evaluate
potential treatments. hiPSCs can be generated from patients with
defined clinical phenotypes, thus enabling in vitro cellular pheno-
types to be linked to individual clinical presentation. Use of hiPSCs
allows the pathogenic mechanisms of different types of mutations to
be evaluated. The potential to have hiPSCs from an unaffected
parent provides a control for genetic background, allowing molecular
and cellular outcomes, including the effect of different mutations on
SATB2 mRNA and protein levels to be efficiently compared.
Importantly, this in vitro system allows for reasonably high
throughput testing of pharmacological agents.
To facilitate patient treatment, it will be important to
elucidate how variability in individual disease pathogenesis
contributes to SAS phenotypes. This variability may derive from
the type of molecular alteration to the SATB2 locus, differences in
genetic background, or even differences in lifestyle. Although
therapies attempting to exogenously supplement reduced protein
levels have achieved little success (Dietz, 2010), it may be
possible to increase the endogenous amount of active protein in
several ways. For example, in individuals with nonsense patho-
genic variants, low levels of SATB2 are thought to result from
NMD of prematurely terminated mRNA transcripts. Several
pharmacological agents are now being used to promote “read‐
through” of stop codons, thus increasing levels of full‐length
mRNA (Baradaran‐Heravi et al., 2017; Landfeldt, Sejersen, &
Tulinius, 2018; Roy et al., 2016). This is an especially attractive
avenue for treatment; however, not all nonsense mutations may
be equally amenable to these treatments as sequences around
the mutation may affect read‐through activity (Bolze, Mocek,
Zimmermann, & Klingenspor, 2017). The power of testing multi-
ple different nonsense mutations in an hiPSC in vitro system has
1026 | ZARATE ET AL.
great potential to elucidate the details of this potential
therapeutic mechanism. Of note, loss‐of‐function mutations may
be amenable to some treatment types that would not alleviate
the effects of dominant negative mutations. Also important to
consider, knowing that SATB2 has an important role in early
neurodevelopment as it has been demonstrated in mice models,
the degree of correction or reversal of cognitive and speech
deficits even if achieving normalization of SATB2 protein levels in
potential human patients treated at later ages could be limited.
SATB2 function is affected by both posttranscriptional regulation
by microRNAs (miRNAs) and posttranslational modification via
sumoylation (Deng et al., 2013; Dobreva et al., 2003; Wei et al.,
2012). While miRNAs regulate amounts of SATB2 protein,
sumoylation affects SATB2 activation potential and association with
endogenous MARs in vivo (Dobreva et al., 2003). Sumoylation targets
SATB2 to the nuclear periphery (Dobreva et al., 2003). Therefore,
inhibiting sumoylation may increase the amount of active SATB2 in
association with MARs.
Another promising approach for the treatment of SAS is to focus
on modifiers that buffer or compensate for reductions in protein
function (Chen et al., 2016). In mice, loss of Satb2 dysregulates the
expression of multiple miRNAs involved in memory and synaptic
plasticity (Jaitner et al., 2016). The effects of dietary supplementa-
tion with phospholipidic concentrates of krill oil and buttermilk on
the expression of miRNAs in hippocampal neurons have been
studied in murine models (Crespo et al., 2018). Finally, neurological
defects in patients with SAS have been reported to share molecular
and cellular mechanisms with other neurodevelopmental or
neurodegenerative diseases, such as schizophrenia and Alzheimer's
disease (Whitton et al., 2018). Therefore, similar treatments could
be explored for these diseases where shared molecular mechanisms
are identified.
8 | CONCLUSION
In this mutation update, we present data from 158 SAS individuals
and review the current state of knowledge and future prospects on
human SATB2 alterations. The 120 unique variants from 155
unrelated families range from single nucleotide variations to complex
genomic rearrangements involving the entire coding region of SATB2.
While germline mosaicism has been found in some instances,
most pathogenic variants have been confirmed to be de novo.
Missense pathogenic variants are often found, and for those studied
functionally, are predicted to act as loss‐of‐protein function
pathogenic variants. Almost invariably, the diagnosis of SAS is made
after molecular investigations are performed and for individuals with
genomic coding variants, next‐generation sequencing technologies
are most often used. Through our extensive review of individuals
with SAS, we present an emerging phenotype that appears more
recognizable with age. Our broad molecular and clinical descriptions
of individuals with SATB2 should help clinicians and families establish
the diagnosis of SAS and develop future therapies.
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